Research
Hormonal
GIP promotes lipogenesis (fat storage) in adipose tissue, while GLP-1 promotes lipolysis (fat breakdown) indirectly via sympathetic nervous system activation.
GIP helps store fat in adipose tissue, while GLP-1 helps break it down. Dual agonists balance these effects to improve overall metabolic health.
GoodSupportsHIGH confidence
GIP directly stimulates lipogenesis, while GLP-1 indirectly promotes lipolysis, collectively maintaining healthy adipocytes, reducing ectopic fat distribution, and increasing the production and secretion of adiponectin from adipocytes.
Why this rating
Supported by abstract and figure legends, with preclinical evidence cited.
Source
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu · Frontiers in Endocrinology · 2024
DOI 10.3389/fendo.2024.1431292
narrative_reviewCited 171×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) and GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss and improve glycemic control in patients with type 2 diabetes and obesity by acting on central satiety centers and peripheral metabolic pathways.Strong
- GLP-1 receptor agonists delay gastric emptying, which reduces postprandial lipid and carbohydrate surges and contributes to satiety.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →